The domestic markets are expected to open in red tracing negative opening in
most of the Asian bourses and the SGX Nifty, as reports say that China has
ruled out any broader stimulus to boost its economy and Spain rating has been
downgraded.
Globally, US markets closed notably higher on Tuesday after witnessing
volatility in the morning trade, which was on account of some mixed news out of
Europe. Most of the European markets also largely finished in positive
territory on Tuesday. Spanish markets, however remained under pressure due to
concerns over the country's banks. Expectations for further stimulus from China
provided investors with optimism, globally.
Meanwhile, Indian benchmark indices gave up most of their early gains on
Tuesday to close flattish, as a little bit of volatility in European markets on
concerns over the outlook for Spanish banks and the slide in rupee following
three days of gains prompted investors to pare their long positions.
Markets Today
The trend deciding level for the day is 16,464 / 4,997 levels. If NIFTY
trades above this level during the first half-an-hour of trade then we may
witness a further rally up to 16,519 – 16,599 / 5,013 – 5,035 levels. However,
if NIFTY trades below 16,464 / 4,997 levels for the first half-an-hour of trade
then it may correct up to 16,384 – 16,330 / 4,975 – 4,959 levels.
IRB emerges L1 for road projects worth Rs.2,400cr
IRB has emerged as the lowest bidder for the four-laning project of
Goa/Karnataka Border to Kundapur section of NH-17 in Karnataka under NHDP phase
IV on design, build, finance, operate and transfer (Toll) basis. The estimated
cost of the project is Rs.2,400cr. The concession period is 28 years and
construction period is 910 days. Further, IRB had sought Rs.536cr as viability
gap funding (VGF) from NHAI. This project win would be after a year as IRB had
won the Ahmedabad-Vadodara project in April 2011. Further, this is in-line with
the company’s guidance of Rs.4,000cr-5,000cr of order inflow each year. We
continue to maintain our Buy recommendation on the stock with a target price of
Rs.166.
Result Reviews
ONGC (CMP: Rs.256, TP: Under Review)
ONGC’s 4QFY2012 results were above our expectations. The company’s top line
increased 22.2% yoy at Rs.18,819cr. EBITDA margin expanded 932bp yoy to 42.6%
and EBITDA increased by 56.4% yoy to Rs.8,019cr. The company’s depreciation and
amortization expenses decreased 41.5% yoy to Rs.1,349cr. Net profit increased
substantially by 102.2% yoy to Rs.5,644cr much ahead of our estimate of
Rs.2,652cr. We recommend a Buy on the Stock with our target price under review.
Tata Motors (CMP: Rs.276 / TP: Rs.312 / Upside: 13%)
Consolidated performance a mixed bag: For 4QFY2012, Tata Motors (TTMT)
reported impressive 44.3% yoy (12.5% qoq) growth in its top line to
Rs.50,908cr, led by 51.5% yoy (10.6% qoq) growth in JLR sales, which were
driven by a 48.2% yoy (13.6% qoq) jump in volumes and 4.4% yoy (flat qoq)
improvement in net average realization. While Land Rover volumes jumped by 51%
yoy, driven mainly by incremental volumes from Evoque (29,171 units during the
quarter), Jaguar volumes jumped by 30% yoy due to the strong performance of the
recently launched XF. The company’s operating margin, however, declined by
184bp qoq and stood at 13.2% primarily on account of increased other
expenditure, which increased substantially by 36.3% qoq. Raw-material expenses,
on the other hand, were stable during the quarter, which supported the margins.
Led by tax credits of Rs.1,793.7cr related to carry forward income tax losses
at JLR, reported net profit jumped sharply to Rs.6,234cr. Adjusted for tax
credits, net profit came in better than expectations, registering 80.5% yoy
growth to Rs.4,440cr.
Strong standalone performance: TTMT posted better-than-expected 14.4% yoy
(22.9% qoq) growth during the quarter on account of 18.5% yoy (23.3% qoq)
growth in volumes. Net average realization, however, declined by 3.6% yoy due
to higher contribution of light commercial vehicles during the quarter.
Operating margin improved substantially by 268bp qoq to 9.1%, mainly led by
operating leverage benefits and a decline in raw-material expenses. Hence, net
profit increased substantially by 225.5% sequentially to Rs.565cr.
At Rs.276, the stock is trading at 6.3x FY2014E earnings. We maintain our
Accumulate rating on the stock with an SOTP target price of Rs.312.
Sun Pharmaceuticals (CMP - Rs.566, TP - Rs.634, Upside: 12%)
Sun Pharmaceuticals reported sales and the net profit came in much ahead of
expectations. For the quarter, the company posted sales of Rs.2330cr, a growth
of 59.4% yoy. The growth in the domestic and exports, both of grew robustly.
The domestic formulations reported growth of 49%, while the US and ROW
formulation sales during the quarter came in at 66% and 31% respectively. On
the operating front, the Gross and Operating margins came in at 78.4% and 41.1%
respectively. The OPM’s were were just in line with expectations. Thus, while
the OPM’s were in line , higher sales growth and higher other income and lower
interest expenses during the quarter aided the net profit growth of 85.3% yoy
to end the period at Rs.820cr, in comparison to the Rs.775cr estimated for the
quarter. We maintain our Accumulate with a target of Rs.634.
SAIL (CMP: Rs.93, TP: Under Review)
SAIL’s 4QFY2012 net sales were above our estimates; however, adjusted PAT
came in below our estimates. SAIL’s 4QFY2012 net sales increased by 12.2% yoy
to Rs.13,397cr (above our estimates of Rs.12,183cr) mainly due to increase in
sales volumes in our view. Raw material costs and other expenditure increased
27.1% and 38.6% yoy to Rs.6,866 and Rs.1979cr, respectively, while power and
fuel costs increased 26.2% yoy to Rs.1,156cr. EBITDA dipped 20.5 % yoy to
Rs.1871cr and EBITDA margin contracted by 574bp yoy to 14.0% (in line with our
estimate of 14.0%). The company reported an exceptional item related to forex
gain of Rs.725cr in 4QFY2012, compared to exceptional gain of Rs.34cr in
4QFY2011. Hence, reported net profit increased by 3.0% yoy to Rs.1577cr.
However, excluding exceptional items, adjusted net profit declined
substantially by 43.1% yoy to Rs.852cr (below our estimate of Rs.1,263cr) in
4QFY2012. We maintain an accumulate rating on the stock keeping our target
price under review
IPCA Labs (CMP - Rs.323, TP - Rs.443, Upside: 37%)
IPCA Labs reported sales and the net profit came in below expectations. For
the quarter, the company posted sales of Rs.553cr, a growth of 16.7% yoy. On
the operating front, the Gross and Operating margins came in at 60.4% and 18.7%
respectively. The OPM’s were below expectations of 20.7%. This aided the net
profit to come at Rs.76.6cr, in comparison to the Rs.64.9cr estimated for the
quarter. We maintain our buy with a target of Rs.443.
Aurobindo Pharma (CMP - Rs.111, TP - Rs.175, Upside: 58%)
Aurobindo Pharmaceuticals reported sales and the net profit came in above
expectations. For the quarter, the company posted sales of Rs.1170cr, a growth
of 2.5% yoy. On the operating front, the Gross and Operating margins came in at
45.2% and 10.3% respectively. The OPM’s were below expectations of 13.9%. This
aided the net profit to come at Rs.38.1cr, in comparison to the Rs.47cr
estimated for the quarter. We maintain our buy with a target of Rs.175.
NCC (CMP: Rs.32, TP: Under review)
For 4QFY2012, NCC posted better-than expected numbers on the revenue and
earnings front however the company disappointed on EBITDAM level. On the top
line front, NCC reported jump of 21.4% yoy to Rs.1,755cr, which was higher than
our expectation of Rs.1,429cr. On the EBITDAM front, the company’s margin were
disappointing at 5.8%, a dip of 320bp on yoy basis and lower than our estimate
of 7.4%. Interest cost came in at Rs.98cr a yoy jump of 19.9% but a decline of
8.1% on sequential basis. On the bottom line level, NCC reported a yoy decline
of 69.7% to Rs.11cr, almost in line with our estimate of Rs.10cr despite
posting higher revenue owing to lower EBITDAM and higher interest cost. The
current outstanding order book of NCC stands at Rs.20,196cr, with order inflow
of Rs.10,116cr for FY2012. We maintain Buy view on the stock however the target
price is under review.
Result Previews
GAIL(CMP: Rs.330 / TP: Rs.392 / Upside: 19%)
GAIL is expected to announce its 4QFY2012 results. We expect the company’s
top line to grow by 20.3% yoy to Rs.10,697cr. However, the company’s operating
margin is expected to contract by 260bp yoy to 11.7%. On the bottom-line front,
we expect GAIL to report growth of 1.9% yoy to Rs.798cr. We continue to
maintain our Buy rating on GAIL with a target price of Rs.392.
Mahindra and Mahindra (CMP: Rs.656 / TP: Rs.793 / Upside: 21%)
Mahindra and Mahindra is slated to announce its 4QFY2012 results. We expect
the company’s top line to grow by strong ~20% yoy to Rs.8,046cr, backed by ~12%
yoy growth in total volumes and ~7% yoy growth in net average realization. The
company’s EBITDA margin is expected to witness a decline of 132bp yoy to 11.4%
on account of increased purchases from its manufacturing subsidiary, MVML, and
lower share of tractors in the total volume mix. As a result, the bottom line
is expected to remain flat on a yoy basis to Rs.610cr. We continue to maintain
our Buy recommendation on the stock with a target price of Rs.793.
DLF (CMP: Rs.188, TP: -, Upside: -)
DLF is expected to announce its 4QFY2012 results. We expect the company’s
top line to decline by 11.2% yoy to Rs.2,382cr. However, the company’s
operating margin is expected to expand by 1,441bp yoy to 39.2%. On the
bottom-line front, we expect DLF to report growth of 29.4% yoy to Rs.446cr. We
continue to maintain our Neutral recommendation on DLF.
Colgate (CMP: Rs.1,216, TP: -, Upside: -)
Colgate is expected to announce its 4QFY2012results. For the quarter, we
expect the company to post 16.4% yoy growth in its top line to Rs.677cr, aided
by volume and realization growth. Net profit for the quarter is expected to
grow by 15.0% yoy to Rs.131cr, aided by margin expansion of 348bp yoy to 25.0%.
We maintain our Neutral view on the stock.
JP Associates (CMP: Rs.62, TP: Rs.98, Upside: 58%)
We expect Jaiprakash Associates (JAL) to post marginal top-line growth of
2.0% yoy to Rs.4,063cr for the quarter on the back of higher revenue
contribution from the cement segment due to capacity addition. We expect the
company to post blended EBITDA margin of 22.9%, an improvement of 150bp yoy for
the quarter. The bottom line is expected to be at Rs.230.6cr, registering a yoy
decline of 23.6% for the quarter. This is mainly on account of a 16.3% yoy
expected jump in interest cost to Rs.470.9cr. We recommend Buy on the stock
with an SOTP target price of Rs.98.
HDIL (CMP: Rs.67, TP: Rs.115, Upside: 72%)
HDIL is expected to announce its 4QFY2012 results. We expect the company’s
top line to increase by 14.8% yoy to Rs.601cr. Operating margin is expected to
expand by 1,105bp yoy to 59.9%. On the bottom-line front, we expect HDIL to
report flat growth on a yoy basis to Rs.197cr. We continue to maintain our Buy
recommendation on HDIL with a target price of Rs.115.
Anant Raj (CMP: Rs.47, TP: Rs.78, Upside: 66%)
Anant Raj is expected to announce its 4QFY2012 results. We expect the
company’s top line to come in at Rs.177cr. However, operating margin is
expected to contract by 2,704bp yoy to 44.7%. The company’s bottom line is
expected to come in at Rs.55cr. We continue to maintain our Buy recommendation
on Anant Raj with a target price of Rs.78.
Simplex Infra (CMP: Rs.212, TP: Rs.316, Upside: 49%)
Simplex Infra is expected to continue its healthy performance on a
sequential basis, as we project 27.1% yoy top-line growth to Rs.1,738cr for
4QFY2012. We expect the company’s EBITDA margin to fall by 100bp to 9.0%. The
bottom line is expected to be under pressure due to increased interest cost
(expected jump of 62.2% yoy), resulting in a yoy decline of 15.1% to Rs.31.4cr
for the quarter. We continue to maintain our Buy view on the stock with a
target price of Rs.316.
GIPCL (CMP: Rs.62, TP: Rs.98, Upside: 58%)
GIPCL is expected to announce its 4QFY2012 results. We expect GIPCL to
register flat top-line performance during the quarter. The company’s OPM is
expected to decline by 1,201bp yoy to 27.4% on a high base on account of lower
plant availability and lesser generation-linked incentives. The first unit of
SLPPI plant (125MW) was not operational during 4QFY2012 due to damaged rotor.
The bottom line is expected to decline by 71.9% yoy to Rs.23cr due to poor
operational performance and higher base due to the tax write-back in 4QFY2011.
We maintain our Buy view on the stock with a target price of Rs.98.
Economic and Political News
- Foreign retail investors can buy US$1bn Indian corporate debt: Govt.
- High Govt. borrowing may crowd out private sector: RBI
- Air India board refers Boeing compensation issue to Govt.
Corporate News
- Jindal Steel's US$2.1bn project gets Bolivian boot
- JSPL buys 10% in Gujarat NREs Oz unit
- Bharat Forge to sell loss-making US unit